There's a lot of buzz around personalized medicine, but what does it really mean? In the first plenary at NACFC, John P. Clancy, M.D., outlined the history of personalized medicine, where we are now and what the future holds. Read on for a quick recap.
Site Search
There have never been as many new CF drugs in development as there are today. In the second plenary at NACFC, Dr. George Retsch-Bogart outlined the progress we've made, the road ahead and the changes needed to make it all possible. Read on for my key takeaways.
This program is intended to promote the role of physical therapy within the cystic fibrosis care team to screen for, prevent, and treat musculoskeletal, cardiovascular, and
This program is intended to facilitate development and implementation of outpatient clinical pharmacy services at care centers and affiliate programs accredited by the Cystic Fibrosis Foundation.
This program is intended to promote greater collaborative integration of statisticians and cystic fibrosis clinical investigators.
The Epithelial
A group of care centers that have expertise in nontuberculous mycobacteria research and treatment have formed a consortium to conduct studies that seek to standardize the diagnosis and treatment of the bacterial infections.
The Therapeutics Development Network Coordinating Center Biostatistics and Clinical Data Management team has extensive expertise in the support of both controlled clinical trials and observational studies. We offer full statistical and data management support -- from planning to implementation to reporting.
The Therapeutics Development Network Coordinating Center can provide coverage and coordination for the review and reporting of serious adverse events that may occur during the course of cystic fibrosis clinical studies.
The Therapeutics Development Network's (TDN) Protocol Review Process ensures optimum safety and quality in cystic fibrosis clinical trial protocols.